University of Manitoba Researchers Explore Genetic Testing for Mental Health Treatment

A research team at the University of Manitoba is actively recruiting individuals seeking mental health treatment for a groundbreaking study that aims to enhance medication effectiveness through genetic testing. This innovative approach seeks to eliminate the uncertainty often associated with finding suitable medications for mental health issues.

The study will provide free pharmacogenomic testing for 200 adults who are either beginning a new medication or switching their current treatment. This type of testing analyzes how a person’s unique genetic makeup may influence their response to various medications, potentially streamlining the process of finding the right treatment.

Dr. Abdullah Maruf, the lead investigator and assistant professor in the College of Pharmacy at the University of Manitoba, emphasized the challenges many patients face. “Individuals with mental health conditions often try multiple medications, which can take months or even years before finding a regimen that works effectively or minimizes side effects,” he explained.

Pharmacogenomic testing has been available privately in Manitoba; however, it typically costs around $500 out of pocket. Currently, there are limited options for coverage through private insurance, and no public health system in Canada offers these tests. Researchers believe that this study could be pivotal in changing that reality.

Dr. Jitender Sareen, head of psychiatry at the University’s Max Rady College of Medicine, highlighted the potential economic benefits of such testing. Citing a 2023 study from British Columbia, he noted that if every patient with depression in the province received genetic testing, it could save the healthcare system approximately $1 billion over two decades. The testing could narrow down medication options from about 40 to as few as five or ten, significantly improving treatment efficiency.

In addition to the potential financial savings, this initiative aims to expedite recovery times for individuals grappling with mental health issues. By utilizing genetic testing, healthcare providers can better tailor treatments, reducing the likelihood of patients becoming frustrated with ineffective therapies or requiring hospitalization.

Many individuals endure prolonged suffering from conditions such as depression and anxiety. Currently, physicians often have limited guidance regarding the most effective treatments for the specific patients they encounter. As Dr. Sareen pointed out, “Our efforts are designed to influence policy, demonstrating that this intervention is cost-effective and a small investment in the healthcare system.”

Uzoma Asagwara, Manitoba’s Health Minister, acknowledged the importance of such research, stating that any proposed additions to the public health system would necessitate a comprehensive evaluation. “We appreciate the efforts of Manitoba researchers and look forward to reviewing the study results once they are available,” Asagwara said in an official statement.

The research team has secured $70,000 from the Health Sciences Centre Foundation and $50,000 from the University of Manitoba’s psychiatry department to cover the costs for the 200 patients over the course of the study, which will run until 2027. Dr. Maruf expressed hope for additional funding to increase patient numbers and explore the potential of genetic testing in reducing hospital stays in Manitoba.

To participate in this study, individuals must obtain a referral from a physician. Eligible patients will need to complete a survey and provide a saliva sample for testing. In Manitoba, more than one in four adults are reported to have a mental illness, underscoring the critical need for effective treatment solutions.

This research initiative represents a significant step forward in the intersection of genetics and mental health, with the potential to reshape treatment paradigms and improve the quality of care for many individuals.